Literature DB >> 11403918

Pro-apoptotic interactions between XK469 and the peripheral benzodiazepine receptor.

D Kessel1, J P Horwitz.   

Abstract

XK469 (2-[4-(7-chloro-2-quinoxalinyloxy) phenoxy]propionic acid) is a new anti-tumor agent with substantial activity against several drug-resistant cell lines. Using murine leukemia L1210 cells in culture, we found the chiral R(+) form of XK469 to be substantially more cytotoxic than the S(-) form, while the herbicide analog 'Assure' was essentially inactive. The cytotoxic response to these agents was accompanied by apoptosis, and was found to be correlated with drug binding to the peripheral benzodiazepine receptor in cell culture, suggesting that receptor binding may be a factor in drug-induced cytotoxicity.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11403918     DOI: 10.1016/s0304-3835(01)00518-3

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  3 in total

1.  A phase I and pharmacokinetic study of XK469R (NSC 698215), a quinoxaline phenoxypropionic acid derivative, in patients with refractory acute leukemia.

Authors:  Wendy Stock; Samir D Undevia; Carol Bivins; Farhad Ravandi; Olatoyosi Odenike; Stefan Faderl; Elizabeth Rich; Gautam Borthakur; Lucy Godley; Srdan Verstovsek; Andrew Artz; William Wierda; Richard A Larson; Yanming Zhang; Jorge Cortes; Mark J Ratain; Francis J Giles
Journal:  Invest New Drugs       Date:  2008-04-19       Impact factor: 3.850

2.  A phase I and pharmacokinetic study of the quinoxaline antitumour Agent R(+)XK469 in patients with advanced solid tumours.

Authors:  Samir D Undevia; Federico Innocenti; Jacqueline Ramirez; Larry House; Apurva A Desai; Linda A Skoog; Deepti A Singh; Theodore Karrison; Hedy L Kindler; Mark J Ratain
Journal:  Eur J Cancer       Date:  2008-07-21       Impact factor: 9.162

3.  R(+)XK469 inhibits hydroxylation of S-warfarin by CYP2C9.

Authors:  Wei Peng Yong; Tae Won Kim; Samir D Undevia; Federico Innocenti; Mark J Ratain
Journal:  Eur J Cancer       Date:  2009-05-21       Impact factor: 9.162

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.